The Latest in High-Grade Neuroendocrine Carcinoma (NEC)： A Conversation with Dr. Chauhan • 2025
In this important update, Dr. Aman Chauhan shares the newest and most promising developments in treatment and research for high-grade neuroendocrine carcinoma (NEC) — a rare and aggressive form of neuroendocrine cancer. For decades, treatment options for NEC have been limited and outcomes have remained largely unchanged. Today, that reality is beginning to shift — and this conversation highlights the progress bringing renewed hope to patients and families. Highlights in This Discussion: DLL3-targeted immunotherapy, including T-cell engagers such as tarlatamab and emerging therapies like Obrixtamig Ongoing progress in clinical trials for high-grade NEC Early success with radiopharmaceutical approaches targeting DLL3 Exploration of oncolytic viruses, including the Seneca Valley Virus combined with ipilimumab (ipi) and nivolumab (nivo) Advances in next-generation immunotherapy, including CAR-T and checkpoint combinations 📍 Want to Learn More? To explore active or upcoming clinical trials for NEC, visit the Neuroendocrine Cancer Foundation’s Clinical Trials Guide at NCF.net/clinical-trials
In this important update, Dr. Aman Chauhan shares the newest and most promising developments in treatment and research for high-grade neuroendocrine carcinoma (NEC) — a rare and aggressive form of neuroendocrine cancer. For decades, treatment options for NEC have been limited and outcomes have remained largely unchanged. Today, that reality is beginning to shift — and this conversation highlights the progress bringing renewed hope to patients and families. Highlights in This Discussion: DLL3-targeted immunotherapy, including T-cell engagers such as tarlatamab and emerging therapies like Obrixtamig Ongoing progress in clinical trials for high-grade NEC Early success with radiopharmaceutical approaches targeting DLL3 Exploration of oncolytic viruses, including the Seneca Valley Virus combined with ipilimumab (ipi) and nivolumab (nivo) Advances in next-generation immunotherapy, including CAR-T and checkpoint combinations 📍 Want to Learn More? To explore active or upcoming clinical trials for NEC, visit the Neuroendocrine Cancer Foundation’s Clinical Trials Guide at NCF.net/clinical-trials